GLP-1受体激素治疗和怀孕:不断发展和新出现的证据
Maria S Varughese1, Fidelma O'Mahony2, Lakshminarayanan Varadhan3
1University of Sheffield Medical School, Royal Hallamshire Hospital, Sheffield S10 2RX, South Yorkshire, UK.
Clinical medicine (London, England)
|February 24, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RA) 对年轻成年人2型糖尿病和肥胖症有前途. 然而,有限的胎儿安全数据需要在使用前进行重要的孕前咨询.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
背景情况:
- 在年轻人中,2型糖尿病 (T2DM) 和肥胖的流行率不断上升,这给生殖健康带来了重大挑战.
- 肥胖和多囊性卵巢综合征 (PCOS) 加剧心血管代谢风险,影响生育能力.
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 正因其在体重管理和血糖控制方面的双重好处以及生殖轴效应而受到关注.
研究的目的:
- 审查目前对T2DM和肥胖年轻人GLP-1RA的理解,重点关注生殖健康影响.
- 为了突出关于使用GLP-1RA的胎儿发育的有限安全数据.
- 为了强调由于潜在的意外胎儿暴露,对孕前咨询的极大需要.
主要方法:
- 关于GLP-1RA,T2DM,肥胖,PCOS和怀孕的研究文献综述.
- 对有关胎儿发育和GLP-1RA暴露的现有安全数据的分析.
- 关于GLP-1RA对生殖轴的影响的综合证据.
主要成果:
- GLP-1RA在治疗T2DM和肥胖方面表现出有效性,对生育能力和代谢风险因素有潜在的益处.
- 关于GLP-1RA,关于胎儿发育的全面安全数据显著缺乏.
- 目前GLP-1RA未经批准在怀孕期间使用,增加了意外暴露的风险.
结论:
- 在开始GLP-1RA治疗前,在患有T2DM或肥胖症的生育年龄妇女中,孕前咨询是必不可少的.
- 迫切需要进一步的研究来确定GLP-1RA对胎儿发育的安全性.
- 将生殖健康考虑因素纳入用GLP-1RA治疗T2DM和肥胖的管理是至关重要的.
相关概念视频
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
Hormonal Regulation
43.1K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.1K
Dipeptidyl Peptidase 4 Inhibitors
163
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
163
Oral Hypoglycemic Agents: Biguanides and Glitazones
158
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
158
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K


